NEATO-ROBOTICS
4.9.2020 13:32:20 CEST | Business Wire | Pressemeddelelse
Neato Robotics, en førende leverandør af intelligente robotstøvsugere til hjemmet, har i dag annonceret lanceringen af de nye modeller i deres kvalitetsserie – Neato D10, D9 og D8 – på IFA Berlin 2020. Neato-robotstøvsugere er den ultimative partner inden for rengøring, idet de har den bedste teknologi i klassen, nem indstilling og hardware, der er skabt til at holde.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200904005047/da/
"Vi har kombineret Neatos 15 års erfaring i branchen med kundefeedback og de seneste nyskabelser inden for robotteknologi og kunstig intelligens, og vi er glade for at kunne introducere disse fantastiske nye produkter – vores bedste indtil nu – for hele verden. Neatos nye serie af intelligente robotstøvsugere er unik i design og teknologi, med en førsteklasses brugeroplevelse og en ny MyNeato-app, som viser vores forpligtelse til at gøre hverdagen nemmere med robotteknologi", siger Neatos CEO, Thomas Nedder.
De nye Neato-robotstøvsugere har kvalitet og brugeroplevelse, der er bedst i deres klasse, samtidig med, at deres D-formede design, som er det første af sin art i branchen, har fået et løft. Neato-ejere kan nå fra hjørne til hjørne og fra kant til kant og få en mere komplet rengøring ved at bruge den bredeste børste og den største støvbeholder på markedet. Neato har det første originale HEPA-filter, og Neato D10 opfanger op til 99,97 % allergener og partikler såsom støv og skæl helt ned til 0,3 my. Det har aldrig været nemmere at indstille en Neato, med en Bluetooth-aktiveret tilslutning til wi-fi og effektiviseret sekstrins-proces på vores nye MyNeato-app – den korteste indstillingsproces i branchen – for straks at komme i gang med rengøringen.
Neato D10
Med en køretid på op til 150 minutter, et originalt HEPA-filter til at opfange op til 99,97 % allergener så små som 0,3 my samt den seneste LaserSmartTM LIDAR-baserede teknologi, er Neato D10 ultraydeevnen til den ultimative rengøring.
Neato D9
Neato D9 gør det beskidte arbejde for dig. Med et ultraydende filter i HEPA-stil, der opfanger 99,5 % støv og allergener, en køretid på op til 120 minutter samt Neatos signatur-teknologi, LaserSmartTM , gør Neato rent når og hvor du ønsker det, også når det er mørkt.
Neato D8
Neato D8 leveres med branchens første signaturkvalitet og -teknologi, som du er vant til at forvente fra Neato – som fx den største støvbeholder, ekstra bred børste og den seneste LaserSmartTM -teknologi – med en bedre brugeroplevelse, en køretid på op til 90 minutter og forbedret effektiv rengøring.
Den nye produktserie vil være tilgængelig i efteråret 2020 hos vores detailhandlere i hele Nordamerika, Europa og Japan, samt i USA på NeatoRobotics.com .
Om Neato
Neato Robotics udvikler intelligente robotter til hjemmet for at gøre livet nemmere for folk og løse reelle problemer. Neato er engageret i at skabe en ægte brugerdefineret rengøringsoplevelse, hvor vi sikrer, at robotterne udvikles og tilpasses til forbrugeren. Neato driver innovation med intelligent LaserSmartTM LIDAR-baseret navigation, kortlægning, smart hjemmeopkobling og uovertruffen rengøringsteknologi. Få mere at vide på www.neatorobotics.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200904005047/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release
Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
